.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

Regulatory Guidance

Ensuring that current and relevant FDA and EMA guidances are applied to the handling of bioanalytical samples during clinical tria

As you work towards a successful New Drug Application (NDA) submission, there are many considerations that must be taken into account, specifically for central nervous system (CNS)-active drugs. Molecules or compounds that are centrally active (the parent drug or metabolite[s]), may require additional evaluations to characterize the drug effects and unique safety characteristics.

Not all centrally acting drugs require additional assessments; however, strategic direction early in a drug development program can help determine whether such studies should be planned or can be waived.  

In Issue 14 of The Altascientist, we look into the complex considerations of CNS-active drugs, including:

  • The landscape of CNS-active drug studies
  • Drug scheduling and the Controlled Substances Act (CSA)
  • Reviewing data from early-phase preclinical and clinical studies
  • Choosing a CRO for CNS studies
 

 

THE IMPORTANCE OF CLINICAL STUDIES FOR CNS-ACTIVE DRUGS

CNS-active drugs have unique attributes that necessitate additional specialized study, such as:

.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

From Lead Candidate to In-life Use – Manufacturing Drugs from Formulation Development to Commercialization

Podcast Speakers:

Steve Schweibenz, President, Manufactur

.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

In this article, we explore key participant retention strategies in Phase I clinical trials.

Altasciences Full-Service Clinical Trial and Bioanalytical Support

We had the pleasure of working with the Altasciences team on a relative bioavailability study, including clinical pharmacology and bioanalytical analysis, for a treatment for palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States.

ON-SITE, ICH STABILITY STORAGE AND TESTING

Equipped with state-of-the-art analytical laboratories and on-site, ICH-compliant stability chambers, our laboratory is ready to handle all your needs.

Our facility offers the standard ICH conditions, as well as custom storage conditions. Our environmental chambers are continuously monitored by Rees Scientific, a centralized monitoring system. Rees Scientific provides us with real-time alerts to ensure samples remain within your desired specifications. All of our stability chambers are on our backup generator.

Current conditions:

  • -80 °C
  • -20 °C
  • 5 °C (walk-in chamber)
  • 25 °C/60% RH (walk-in chamber)
  • 30 °C/65% RH
  • 30 °C/75% RH
  • 40 °C/75% RH
Subscribe to